Top Engineered zymogen may be useful drug Nature often keeps protein-cleaving enzymes known as proteases under tight control by synthesizing them in an inactive form called a zymogen, which becomes active only after another protease cleaves a specific peptide bond. Now, a team led by biochemistry and chemistry professor Ronald T.
February 03, 2003
/articles/90/i25/New-Way-Hit-Alzheimers-Target.html 20120618 Drug Discovery: Agent with novel mechanism improves selectivity for caspase-6 enzyme News of The Week 90 25 /magazine/90/09025.html New Way To Hit Alzheimer’s Target: Caspase-6 Inhibitor Alzheimer’s, caspase, zymogen, inhibitor notw scitech Stu Borman pharmaceuticals Ribbon (left) and space-filling representations of a tetramer of caspase-6 precursor induced to form by two molecules of pep419.
by Stu Borman | June 18, 2012
They are also trying to extend their enzyme-modification concept to other diseases and to antiviral applications by creating synthetic zymogens, inactive enzyme precursors that can be activated by disease-specific enzymes in vivo. Nathanael S. Gray of Dana-Farber Cancer Institute and the department of biological chemistry and molecular pharmacology at Harvard Medical School discussed his group's recent screening of a combinatorial heterocycle library for inhibitors of Bcr-abl, a tyrosine kinase encoded by an abnormal chromosome found in about 95% of people with chronic myelogenous leukemia (Nat.
by Stu Borman | October 01, 2007